Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. Using the Pept-in™ platform technology, Aelin can create a complete new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.
The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science.
Website
The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science.
Website
Location: Belgium, Flemish Brabant, Heverlee
Investors 3
| Date | Name | Website |
| - | Fund+ | fundplus.b... |
| - | KU Leuven ... | lrd.kuleuv... |
| - | Life Scien... | lspvc.com |
Mentions in press and media 1
| Date | Title | Description |
| 20.10.2023 | How is Pept-In Technology Revolutionizing the Biotherapeutics and Healthcare Industry? | Key Takeaways: Aelin Therapeutics, a Belgian-based startup, uses Pept-in technology to revolutionize the biotherapeutics industry. The Pept-In technology uniquely targets intracellular space that is usually unreachable by typical treatments... |